Articular cartilage serves as the gliding surface of joints. It is susceptible to damage from trauma and from degenerative diseases. Restoration of damaged articular cartilage may be achievable through the use of cell-regulatory molecules that augment the reparative activities of the cells, inhibit the cells' degradative activities, or both. A variety of such molecules have been identified. These include insulin-like growth factor I, fibroblast growth factor 2, bone morphogenetic proteins 2, 4, and 7, and interleukin-1 receptor antagonist. It is now possible to transfer the genes encoding such molecules into articular cartilage and synovial lining cells. Although preliminary, data from in-vitro and in-vivo studies suggest that gene therapy can deliver such potentially therapeutic agents to protect existing cartilage and to build new cartilage.
INTRODUCTION
Articular cartilage is unusual in lacking an effective intrinsic capacity to repair itself when damaged. It lacks a blood supply and, as a result, does not have Damaged articular cartilage is an unsolved problem in modern orthopaedics. Articular cartilage is the access to the reparative cells that are brought into sites of injury in nearly all other tissues in the body. tissue which lines the weight-bearing surface of joints. Its extraordinarily low coefficient of friction enables Thus, defects caused by acute trauma tend to persist, and the loss of cartilage associated with arthritis the smooth supple pain-free motion of joints. Indeed, early in life, it is generally possible to take smooth tends to be inexorably progressive [2] . Current medical treatments for arthritis are highly pain-free joint motion for granted. Unfortunately, articular cartilage damage, manifested clinically as effective in reducing the pain that it causes. However, such treatments are ineffective in reversing the arthritis, becomes increasingly prevalent with increasing age. Arthritis afflicts over one third of Americans course of the disease. As a result, the ultimate fate of many arthritic joints is total joint replacement who are 60-65 years old, and nearly half of those 70-75 years of age [1] . Because the elderly are one of surgery by implantation of metal, plastic, or ceramic bearing surfaces as substitutes for the articular carti-the most rapidly growing segments of the population in the USA and elsewhere, the problem of articular lage surface. Although such surgery arrests the course of the disease, it does so not by restoring the cartilage damage is increasing in scope. Injury to this tissue may also occur in youth. Trauma to joints can cartilage to normal, but by removing it altogether. Such surgery also sets in motion a new form of pro-acutely damage articular cartilage. A typical example is the focal loss of articular cartilage that occurs in gressive disease, that of joint replacement failure. Many replaced joints fail through mechanisms such athletic injuries to the knee. Although less common than arthritis, this form of articular cartilage damage as wear, loosening, infection, and breakage. This leads to further surgery to revise the replaced joint can be similarly disabling.
that has failed, but the results of revision joint include surgical recruitment of subchondral cells The specific goal of the gene therapy determines the specific protein, and hence the specific gene, [3, 4], cell implantation [5, 6], and tissue implantation [3, 5, 6]. All these treatments have had some selected for use. A growth factor gene may be used if the goal of gene therapy is to alter the behaviour clinical success, but none reliably restores the cartilage to normal and efforts are ongoing to improve of surrounding cells. A gene encoding an enzyme inhibitor may be selected if the goal is to inhibit carti-upon current articular cartilage repair methods.
A major hurdle to the development of effective lage matrix degradation. Gene therapy may be viewed as a drug delivery system that is able to therapies for articular cartilage repair is the lack of a basic understanding of how cartilage is regulated in deliver an essentially pure agent to a highly specific location in a delayed-release fashion. The technology the normal joint and how this regulation is disrupted in the arthritic joint. Despite this limited understand-for achieving gene transfer and protein production is, however, not simple and is still under develop-ing, it is possible to view the 'cause' of arthritis as an imbalance in articular cartilage homeostasis: ment. loss of articular cartilage occurs when the level of anabolic activity in the tissue falls below the level of the catabolic activity [7] . From this perspective, one 3 SELECTION OF GENES FOR GENE THERAPY approach to reversing the progress of articular cartilage damage would be to augment articular cartilage An important advantage of gene transfer as a potential approach to therapy for cartilage repair is the anabolic activities and/or to reduce its catabolic activities [8] .
wide variety of molecules that have been found to augment the anabolic activity of articular chondro-Considerable progress has been made in the last few years in identifying biological factors that aug-cytes. Most of these molecules are proteins that function as cell-signalling agents that regulate cell ment the reparative activity of articular chondrocytes, and also in identifying those responsible for behaviour. Harnessing this action has been achieved for several growth factors in in-vitro and in-vivo cartilage degradation. Less progress has been made in developing methods of delivering these sub-models. Insulin-like growth factor I (IGF-I) stimulates synthesis by chondrocytes of the two major building stances to damaged joints in a fashion that effectively restores the cartilage. For example, even when a pro-blocks of articular cartilage: aggrecan [11] and type II collagen [12] . It also has a mild stimulatory effect tein that is known to stimulate cartilage repair or inhibit cartilage degradation is delivered to a joint, it on chondrocyte proliferation and inhibits chondrocyte degradation of its surrounding matrix [13] . may be ineffective because of rapid clearance from the joint, or difficulty getting through the articular Fibroblast growth factor 2 (FGF-2) is mitogenic for chondrocytes but appears to be capable of stimulat-cartilage matrix to act on the chondrocytes that it is intended to stimulate [9, 10]. These problems may ing both reparative and degradative behaviour in articular cartilage [8] . Members of the transforming potentially be resolved by gene transfer technology. growth factor (TGF-b) superfamily, including the bone morphogenetic proteins (BMPs), are potent regulators of chondrocytes. For example, in vitro, 2 PRINCIPLES OF GENE THERAPY BMP-2 maintained the articular chondrocyte phenotype in a long-term culture [14] and, in vivo, BMP-2 Gene therapy is based on the principle that proteins, including therapeutic proteins, are encoded by seg-significantly improved the repair of articular cartilage defects in rabbit knees analysed 1 year after treat-ments of deoxyribonucleic acid (DNA), or genes. A specific DNA sequence serves as a template for the ment [15]. synthesis of a corresponding specific messenger ribonucleic acid (mRNA). The construction of the mRNA, termed transcription, occurs within the cell's 4 CULTURE MODELS OF GENE TRANSFER nucleus. The mRNA, in turn, serves as the template for the synthesis of a specific protein. The construc-
In-vitro models of chondrocyte gene transfer include two-dimensional and three-dimensional cell cul-tion of the protein, termed translation, occurs in the cell cytoplasm. The protein may then be secreted tures. The effect of overexpression of several genes has been studied in two-dimensional models, includ-into the extra-cellular environment. Gene therapy is simply the insertion of a gene into a cell so that the ing IGF-I [16-18], BMP-2 [18] , and TGF-b-1 [18, 19] . Three-dimensional systems more closely resemble cell now manufactures (through transcription and then translation) the desired protein.
the in-vivo environment of native chondrocytes embedded within their matrix. These conditions 5 ANIMAL MODELS OF GENE TRANSFER enable chondrocytes to assume a spherical shape Among the first genes to be investigated in vivo and to avoid the phenotypic drift that may occur was interleukin-1 receptor antagonist (IL-1Ra). Interwhen chondrocytes are grown and passaged over leukin-1 is a cytokine produced by synovial cells and extended periods of time in monolayer [20, 21] .
chondrocytes that appears to incite cartilage damage Three-dimensional systems that have been used for in arthritis [34] . IL-1Ra is a protein that inhibits gene transfer include pellet cultures [22] , the transthe catabolic actions of interleukin-1. IL-1Ra gene plantation of genetically modified chondrocytes on therapy has been investigated in mouse [35] , rat [36] , to cartilage explants [23] [24] [25] [26] , the creation of genetirabbit [37] [38] [39] , canine [40], and equine [41] models cally modified tissue-engineered cartilage by attachof cartilage damage. The treatment reduced articular ing modified chondrocytes to biomaterials such as cartilage damage [38] [39] [40] and also reduced clinical polyglycolic acid [27] , or the encapsulation of genetisigns of disease in the equine model [41] . IL-1Ra was cally modified chondrocytes in hydrogels such as also used in the first human arthritis gene therapy alginate [28] [29] [30] [31] .
trial [42] . In this study, the IL-1Ra gene was delivered The transplantation of genetically modified chondin autologous synovial cells to the hand joints of rocytes on to articular cartilage explants in vitro patients with rheumatoid arthritis. At the time of creates a chimeric tissue composed of modified cells joint surgery 1 week later, the IL-1Ra gene was shown transplanted on to articular cartilage [23] [24] [25] [26] 32] .
to be expressed and IL-Ra protein was found in the This model permits the study of the effect of a potenjoint. tial therapeutic gene on the formation of new carti-Other promising candidates for gene therapy are laginous tissue as well as on the underlying host growth factors that stimulate anabolic activities by cartilage. Transplantation of articular chondrocytes articular chondrocytes. These include IGF-I, FGF-2, that overexpressed human IGF-I was shown in such TGF-b, BMP-2, and BMP-7. IGF-I gene transfer into a model to both stimulate chondrocyte proliferation articular chondrocytes stimulated chondrocyte proand matrix synthesis in the new tissue, and to liferation and matrix synthesis and augmented the increase DNA and glycosaminoglycan synthesis by formation of neocartilage in in-vitro [16, 26] and the underlying explant cartilage chondrocytes. These in-vivo [31, 43, 44] models of articular cartilage results suggest a paracrine effect of the secreted gene repair. Similar results have been obtained with FGF-2 product on distant chondrocytes embedded within in vitro [25] and in vivo [45] [46] [47] . Direct intra-articular their native matrix [26] . Transplantation of chondrotransfer of the TGF-b gene raised intra-articular cytes transduced with an adenoviral BMP-7 vector TGF-b protein levels [48] and intra-articular injection also led to thicker new tissue in this model, suggestof fibroblasts transduced with the TGF-b gene stimuing an enhanced matrix synthesis [24] . In contrast, lated cartilage repair in a cartilage defect model [49] . when chondrocytes overexpressing human FGF-2
Conversely, intra-articular gene transfer of a TGF-b were transplanted, the cells in the new tissue showed inhibitor increased articular cartilage proteoglycan a selective stimulation of mitogenic without effects loss [50] . Gene transfer using BMP-2 [43] , BMP-4 on matrix synthesis [25] .
[51], and BMP-7 [52, 53] augmented intra-articular Cartilage tissue engineering may also be improved cartilage formation in in-vivo models. by the application of gene transfer technology. Transfection of articular chondrocytes with human IGF-I complementary deoxyribonucleic acid (cDNA) 6 TYPES OF GENE THERAPY augmented the structural and functional properties of tissue engineered cartilaginous constructs based 6.1 In-vitro gene therapy on a polyglycolic acid scaffold and generated in a bioreactor [27] . The biosynthetic activity of chondro-In-vitro gene therapy entails the insertion of the cytes encapsulated in alginate spheres was enhanced desired gene (transgene) into the recipient cells in a by IGF-I [31] and FGF-2 [29] gene transfer. Similarly, cell or tissue culture environment. The cells are then the transfer of SOX9, a transcription factor that placed into the relevant site in the body. This has the acts only intracellularly, stimulated type-II collagen advantage of enabling gene transfer into a specific expression in alginate spheres [33] , and in pellet culpopulation of cells, and the ability to test the cells tures [22] . This finding suggests that tissue engineerfor successful gene expression. In-vitro methods ing coupled with gene therapy based on intracrine have been used to deliver reporter genes [54], IGF-I [16, 26], FGF-2 [25] , BMP-2 [43] , BMP-4 [51], BMP-7 mechanisms may be feasible. [52, 53] , TGF-b [49] , and IL-1Ra [35, 37] . This is the ing a charge differential across the cell membrane. Although this method has been applied to chondro-approach that was approved and then used in the published human gene therapy study of IL-1Ra for cytes [58] , its use has not been widespread. A variety of cationic liposomes and other lipid-based systems rheumatoid arthritis of the hand [42] . When using adenoviral vectors, the in-vitro method has been have developed for gene transfer and are commercially available. In a study that systematically com-shown to reduce the immune response that this vector may elicit when used by in-vivo methods [43] .
pared the ability of several cationic lipid preparations to transfect bovine articular chondrocytes, consider-In-vitro gene therapeutic approaches also have the advantage of delivering cells that may contribute to able differences were found among these reagents [59] . Transfection with these lipid-based reagents the repair process. This may be of particular value for the treatment of focal articular cartilage defects may be substantially increased by the use of cotransfection agents [59] . Thus, a limitation of these using anabolic factors such as IGF-I, FGF-2, and TGF-b, in which cells are needed to fill the site of reagents is their sensitivity to cell type and transfection conditions. Such non-viral gene transfer damage.
methods have the advantage of avoiding the risk of insertional mutagenesis of retroviruses, the risk of 6.2 In-vivo gene therapy immunogenicity of adenoviruses, or the size limi-In-vivo gene therapy involves the delivery of the tation on transferred DNA that is associated with desired gene directly into the body. This method has AAVs. Non-viral methods also avoid the risk of the advantage of avoiding the extra steps involved acquiring viral competence. Because non-viral gene in cell harvest, isolation, culture, and subsequent transfer does not place the therapeutic gene into the delivery. In theory, it should reduce the risk of comcell genome, the transferred gene (transgene) is not plications such as cell contamination or phenotypic transmitted to daughter cells if the cell divides. The shifts, and the magnitude of processing costs. In-vivo episomal (not integrated into the host cell genome) approaches may be particularly suitable for gene location of the transgene also destines the transgene delivery to the synovium because these cells are to be expressed for only a transient time period. This readily accessible to injected agents. Articular chondtransient expression is of great safety value for anarocytes, in contrast, are embedded within a matrix bolic genes whose product could cause excessive that restricts diffusion of injected agents and may be growth if overexpressed for prolonged periods. Howexpected to limit the access of such agents to the ever, this feature also limits the potential value of the chondrocytes. This approach has been applied in method for chronic disorders that require longcartilage damage models to the delivery of IL-1Ra lasting output of the gene product. [36, 38, 39, 41] , BMP-2 [43] , IGF-I [44] , FGF-2 [46] , TGF-b inhibitor [50], interleukin-4 [55], and the 7.2 Viral gene delivery soluble tumour necrosis factor receptor 1 [56] .
Localized in-vivo gene therapy could, in theory, Viruses in nature evolved to transfer genetic material. The life cycle of wild-type viruses involves the trans-reduce the disadvantages of systemic viral dissemination. When adeno-associated virus (AAV) vectors fer of viral DNA or RNA into host cells. Virus-based gene therapy builds on this innate ability by adding were applied to articular cartilage defects by open arthrotomy in the rat [57] or rabbit [46] knee, potentially therapeutic genes to the viral sequence and, in some instances, by also removing portions transgene product was subsequently found in the defect repair tissue but, in both models, transgene of the viral genome that enable the viruses to be harmful. product was also noted in the synovium. These results indicate that, even with localized in-vivo delivery into a joint, at least some systemic distribution 7.3 Retrovirus vectors may occur.
Retroviruses include such evolutionarily successful viruses as human immunodeficiency virus and human T-lymphotropic viruses. An important advan-7 GENE DELIVERY AGENTS tage of these viruses for gene therapy is their ability to incorporate into the genome of the host cell. This
Non-viral gene delivery
enables the transferred gene to be replicated during cell division and to achieve long-term expression over A popular approach to transferring DNA into cells employs physicochemical methods. Electroporation multiple cell generations. However, this feature also imposes the safety issue of insertional mutagenesis. enables DNA to cross the cells membrane by generat-This may occur when the transferred gene is inserted relatively small (up to about 4.7 kilobases) genes. This limitation may be resolved by exploiting the into a region of the host cell's DNA in such a way that the insertion disrupts the function of a normal gene.
attractive feature of rAAV genomes that they can be linked together to increase the size of the genes to For example, by disrupting the function of a tumour suppressor gene, the gene transfer may inadvertently be transferred [68, 69]. promote cancer. This phenomenon has been blamed for the development of leukaemia in some children 7.6 Lentivirus vectors who received retroviral gene therapy in the late 1990s
Lentiviruses are a relative of retroviruses. Lentivirus [60] . Additional limitations of retroviruses as vectors vectors are distinguished from oncogenic retrovirus are their inability to infect non-dividing cells and the vectors by their ability to transduce non-dividing need for special culture procedures to identify and cells. Lentivirus vector-based gene delivery can select cells that contain the transgene. Retroviruses generate long-term transgene expression by incorpohave, however, been demonstrated to be feasible rating transgenes into the host cell genome. Two vectors for delivering exogenous genes to sites of additional advantages of these vectors are their articular cartilage damage [51, 61] .
ability to deliver large cDNAs into target cells and to do so without inducing a host immune response 7.4 Adenovirus vectors against the transduced cells [70]. Lentivirus vectors Adenovirus vectors are among the most successful have been successfully used to deliver genes to synovectors available for gene transfer. They often genervium in vivo [71] and to chondrocytes in vitro [72] . ate high transfection efficiency and high levels of
The safety of these vectors and the regulation of transgene product in a variety of cell types. Adenoexpression of their transgenes are currently under viral vectors have been used in in-vitro and in-vivo investigation. models of cartilage damage, including models of inflamatory arthritis [44] , osteoarthritis [41, 48] , and chondral defects [32, 53, 62] . They are the only viral 8 FUTURE DIRECTIONS vector used to date in human joint disease [42] . Unfortunately, adenoviral vectors are often immuno-
The potential applications of gene therapy for cartigenic and may stimulate a host response. This reaclage repair are many. Gene transfer technology can, tion may be severe and led to the highly publicized in theory, be applied to inflammatory joint disease death of a gene therapy patient in a phase I clinical such as rheumatoid arthritis, degenerative joint trial [63] . Even in milder form, this phenomenon may disease such as osteoarthritis or post-traumatic be problematic. In the field of cartilage gene therapy, arthritis, and to acute cartilage loss, such as damage it is thought to be responsible for the paradoxical due to athletic injuries. Considerable progress has inhibition of proteoglycan synthesis in chondrocytes been made in bringing these applications towards that received the IL-1Ra gene, a treatment that would fruition in articular cartilage disease. The technology be expected to have the opposite effect [64] .
has been shown to be effective at a proof-of-concept level for all these applications in both in-vitro and 7.5 Adeno-associated virus vectors in-vivo models. However, many unanswered questions remain (Table 1) . What is the optimal vector? Is AAVs are replication-defective parvoviruses that have the advantage, for gene therapy, of being non-in-vivo gene therapy superior to in-vitro gene therapy, or vice versa? What is the short-term and, perhaps pathogenic in humans. They lack the immunogenicity of adenoviruses and the risk of insertional more importantly, the long-term safety of the genes and gene products that would be used to treat joint mutagenesis of retroviruses. Early experience with recombinant AAVs suggests that these viruses may disease? Is gene transfer technology robust enough to be useful on its own, or should efforts be intensi-serve as effective vectors for chondrocyte and synovial cell transfection in vitro [45, 57, 65] and in vivo fied to combine it with tissue engineering technology? Probably, the answer to all of these questions [36, 46, 47, 55, 56, 66, 67] . To date, however, available data on these vectors remains limited in comparison is 'it depends'. Just as the disorders that afflict cartilage are diverse and of multifactorial aetiology, with adenoviral vectors. Both an advantage and a limitation of AAVs as a gene therapy vector is its size. so effective treatments for them will be diverse and will probably require multiple elements. As ongoing As a particularly small virus, it may have access to sites that are not accessible to larger viral vectors.
research provides answers to these questions, and as understanding of the mechanisms underlying However, its size also means that it can hold only 
